New bispecific antibodies in diffuse large B-cell lymphoma.

With a median follow-up of 20.7 months, this translated into a highly significant improvement of progression-free survival (median 13.8 vs. 3.6 months; hazard ratio=0.40 [95% confidence interval: 0.28-0.57]; P <0.001) and overall survival (median 25.5 vs. 12.9 months; hazard ratio=0.62 [95% confidence interval: 0.43-0.88]; P =0.006).

also in 132,142 other papers

For each of glofitamab, epcoritamab and odronextamab, responders showed a trend towards higher baseline tumor CD8 + T-cell infiltration via a variety of techniques, although nuances appear to be important. 40-42 For instance, a specific increase in an effector-like CD8 + T-cell subset was associated with complete response to glofitamab, as was a naïve phenotype. 42 , 43 Increa

also in 53,322 other papers